RE:RE:RE:RE:RE:RE:RE:Are we halted ?Your belief about how TLD-1433 "deserved" to be trialled is beside the point. Did Theralase request this of the FDA and were not "permitted"? Or did Theralase submit the exact protocol they wanted to - for BCG-unresponsive NMIBC?
fredgoodwinson wrote: This reasoning is in the context of a belief (which I strongly expressed at the time of the Clinical Protocol) that on the basis of the preclinical evidence TLD-1433 deserved to be trialled as a first-line treatment against early stage disease. Many lesser prospects had and have been permitted this setting.